This is an old, old problem, though, and a reason to use heritage seed and produce more.
It's rather obvious that they have the greatest conflict of interest. Not only do germline genetic repairs compete with their intellectual property for patients to cure, they threaten to reduce common genetic maladies as a profit center, like a communicable disease treatable with a lucrative antibiotic being eliminated would deprofit the antibiotic manufacturer.
Listen to what one critic wrote in Nature: "Philosophically or ethically justifiable applications for this technology â" should any ever exist â" are moot until it becomes possible to demonstrate safe outcomes and obtain reproducible data over multiple generations."
Jeeze - treatments for fatal diseases aren't justifiable until after they've been used for multiple generations already to demonstrate safe outcomes? Way to set a conveniently impossible bar. And absurd, compared to the standards for any other medical treatment. They are more interested in patents than patients.
As to the parent comment, you don't encourage innovation by eliminating competing approaches. Unless you're a utterly slimy-selfish dolt.
You are always doing something marginal when the boss drops by your desk.